- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Repligen Corporation (RGEN)Repligen Corporation stock price live, this page displays NASDAQ RGEN stock exchange data. View the RGEN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Repligen Corporation real time stock price chart below.
What Is the Repligen Corporation Stock Price Today?
The Repligen Corporation stock price today is 144.75.
What Is the Stock Symbol for Repligen Corporation?
The stock symbol for Repligen Corporation is "RGEN."
What Stock Exchange Does Repligen Corporation Trade On?
Repligen Corporation is listed and trades on the NASDAQ stock exchange.
Is Repligen Corporation a Good Stock to Buy?
Determining whether Repligen Corporation—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RGEN quote. (ISIN: US7599161095)
What Is the Repligen Corporation Stock Price Today?
The Repligen Corporation stock price today is 144.75.
What Is the Stock Symbol for Repligen Corporation?
The stock symbol for Repligen Corporation is "RGEN."
What Stock Exchange Does Repligen Corporation Trade On?
Repligen Corporation is listed and trades on the NASDAQ stock exchange.
Is Repligen Corporation a Good Stock to Buy?
Determining whether Repligen Corporation—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RGEN quote. (ISIN: US7599161095)
144.75
-4.35(-2.91%)
Real-time Data
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
144.02
148.17
52 wk Range
113.50
211.13
RGEN Scorecard
Full Analysis
Net income is expected to grow this year
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
144.02148.17
52 wk Range
113.50211.13
Key Statistics
Edit
Book Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockRGEN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Neutral
Price Target
192.25
Upside
+32.82%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
12 analysts have revised their earnings downwards for the upcoming period
- Repligen Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Repligen director Hunt sells $3.39 million in stock
- Investing.com
- Repligen director Hunt sells $3.39 million in stock
- Investing.com
- Repligen Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Repligen Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Repligen Corporation Company Profile
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Repligen Corporation SWOT Analysis
Bioprocessing Pionee | Repligen leads in bioprocessing technologies, specializing in crucial components for biologic drug development and manufacturing, with a focus on emerging therapies. |
Market Recovery Signs | Explore Repligen's improving book-to-bill ratio and order uptick from pharma companies, signaling potential growth amid industry-wide bioprocessing sector recovery. |
Strategic Growth Path | Delve into Repligen's dual-pronged growth strategy: organic initiatives and strategic acquisitions, including the recent Tantti purchase and exploration of larger M&A opportunities. |
Financial Projections | Analysts anticipate double-digit growth for Repligen, with projections to more than double earnings power by 2027. Price targets range from $155 to $205. |
RGEN Full Pro Research
Institutional-Grade Stock Analysis
Understand how RGEN earns money
Financial health at a glance
Bearish and bullish outlooks
Latest expert insights
Actionable Pro Tips, and many more...
Gain access to 1400+ in-depth research reports on the most popular US stocks
Repligen Corporation Earnings Call Summary for Q3/2024
- Q2 revenue declined 3% YoY to $154M; 2024 guidance narrowed to $620-635M due to China headwinds and forex impact
- Non-COVID growth projected at 11%; strong H2 expected with adjusted operating margin of 12-13% and EBITDA margins of 17-18%
- Tangenx product demand up 30% YoY; chromatography demand increased over 50% in Q2
- Key account strategy covering 20 top accounts successful; company optimistic about future growth from new modalities
- Repligen anticipates stronger H2 2024 revenue growth; plans to discuss 2025 outlook at year-end, aiming for above-market growth
Last Updated: 01/08/2024, 05:46 am
Read Full TranscriptCompare RGEN to Peers and Sector
Metrics to compare | RGEN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRGENPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1,031.9x | −11.8x | −0.7x | |
PEG Ratio | 9.54 | −0.55 | 0.00 | |
Price/Book | 4.1x | 2.2x | 2.6x | |
Price / LTM Sales | 13.2x | 2.7x | 3.2x | |
Upside (Analyst Target) | 27.4% | 27.4% | 45.9% | |
Fair Value Upside | Unlock | 0.4% | 7.6% | Unlock |
Analysts' Recommendations
12 Buy
4 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 192.25
(+32.82% Upside)
People Also Watch
FAQ
What Is the Repligen (RGEN) Stock Price Today?
The Repligen stock price today is 144.75
What Stock Exchange Does Repligen Trade On?
Repligen is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Repligen?
The stock symbol for Repligen is "RGEN."
What Is the Repligen Market Cap?
As of today, Repligen market cap is 8.10B.
What is Repligen Earnings Per Share?
The Repligen EPS is -0.145.
What Is the Next Repligen Earnings Date?
Repligen will release its next earnings report on 18 Feb 2025.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.